NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Medical Devices · USD

VolitionRx Limited (VNRX) Stock Analysis

VolitionRx Limited (VNRX) is a Medical Devices stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

VNRX

$0.17

−$0.01 (−3.93%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VNRX with… →

VNRX Key Statistics

As of Oct 21, 2026
Trading
Open
$0.17
Previous Close
$0.17
Day's Range
0.16–0.17
52-Week Range
0.16–9.60
Volume
466.79K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.17
Valuation
Market Cap
$5.00M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.03
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.80
Financials (FY)
Revenue (FY)
$1.73M+40.04%
Net Income (FY)
−$23.36M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
30.06M
1-Year Return
−98.07%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
8.58M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VNRX closed at $0.17, −98.07% over 1 year.

VolitionRx Limited (VNRX) has a market capitalization of $5.00M.

In fiscal 2025, VNRX reported revenue of $1.73M.

VNRX Stock Return by Calendar Year

VolitionRx Limited (VNRX) 10-year return: what $10,000 became

1 year
$10,000 $193
−98.07%
5 years
$10,000 $24
−99.76%
10 years
$10,000 $17
−99.83%

If you had invested $10,000 in VolitionRx Limited (VNRX) 10 years ago, at the close on October 21, 2016, it would have been worth $17 at the close on October 21, 2026: −99.83% in total, −47.10% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−96.80%
2025−56.67%
2024−16.67%
2023−70.37%
2022−22.61%
2021−19.28%
2020−17.93%
2019+161.88%
2018−38.44%
2017−35.67%
2016 (partial year)+36.01%

As of October 21, 2026.

VNRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.73M−$23.36M−1,352.2%
2024$1.23M−$26.97M−2,186.3%
2023$775.30K−$35.32M−4,555.5%
2022$306.39K−$30.27M−9,879.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.73M—−$21.22M−$23.36M−1,352.2%
2024$1.23M—−$26.92M−$26.97M−2,186.3%
2023$775.30K—−$35.77M−$35.32M−4,555.5%
2022$306.39K—−$30.55M−$30.27M−9,879.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VNRX Valuation vs Medical Devices Median

Median of 145 stocks
MetricVNRXMedical Devices medianvs median
P/S ratio2.032.5320% below

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values VolitionRx Limited (VNRX) at $5.00M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 57.

Over the past 52 weeks the price has ranged from $0.16 to $9.60. The most recent close on file for VNRX is $0.17, dated October 21, 2026. That is −$0.01 (−3.93%) against the previous close. The latest close sits 4% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.73M. Against the prior fiscal year total of $1.23M, that is a change of +40.04%. The same year closed with a net loss of $23.36M. Trailing earnings per share are −3.8.

Across the 4 fiscal years on file, revenue moves from $306.39K in 2022 to $1.73M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 2.03 times revenue. On price-to-sales that is 19.56% below the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.17. Daily returns over the trailing 10 years annualize to a volatility of 83.34%. Over the trailing twelve months the total return is −98.07%. Measured over 10 years, that is −47.10% a year compounded.

Growth & Income

The record shows no dividend for VNRX.

Across the complete calendar years on file, 2019 returned +161.88% and 2023 returned −70.37%. Of the 9 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −96.80%.

Peer Comparison

VolitionRx Limited (VNRX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
VolitionRx Limited VNRX $5.00M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. VolitionRx Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About VolitionRx Limited

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Visit website →